Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
暂无分享,去创建一个
C. Stedman | G. Cooke | G. Dore | M. Nelson | S. Bhagani | E. Gane | D. Shaw | J. Grebely | M. Martinello | G. Matthews | R. Kulasegaram | E. Tu | A. Ustianowski | D. Iser | C. Orkin
[1] Philippa J Easterbrook,et al. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. , 2023, The lancet. Gastroenterology & hepatology.
[2] J. Ward,et al. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. , 2022, The International journal on drug policy.
[3] M. Manns,et al. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study , 2022, JHEP reports : innovation in hepatology.
[4] Jisoo A. Kwon,et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.
[5] P. Read,et al. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. , 2021, Journal of hepatology.
[6] F. Luciani,et al. Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis , 2020, Nature Communications.
[7] C. Boesecke. Recently acquired and early chronic hepatitis C in men having sex with men (MSM): Recommendations from the NEAT-ID consensus panel. , 2020, AIDS.
[8] G. Cooke,et al. Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection , 2020, Hepatology.
[9] Y. Yazdanpanah,et al. Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. , 2020, The Journal of antimicrobial chemotherapy.
[10] A. Lok,et al. Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy. , 2019, Gastroenterology.
[11] G. Lauer,et al. Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[12] W. Bierman,et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. , 2019, The lancet. Gastroenterology & hepatology.
[13] M. Hughes,et al. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] G. Cooke,et al. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection , 2018, Journal of viral hepatitis.
[15] G. Dore,et al. Management of acute HCV infection in the era of direct-acting antiviral therapy , 2018, Nature Reviews Gastroenterology & Hepatology.
[16] O. Weiland,et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. , 2018, Journal of hepatology.
[17] J. Chhatwal,et al. Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis , 2018, Hepatology.
[18] T. Asselah,et al. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.
[19] M. Manns,et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.
[20] J. Rockstroh,et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. , 2017, The lancet. Gastroenterology & hepatology.
[21] M. Manns,et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. , 2017, The Lancet. Infectious diseases.
[22] A. Howe,et al. Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial , 2017, Hepatology.
[23] M. Hellard,et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study , 2016, Hepatology.
[24] H. Dahari,et al. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. , 2016, Journal of hepatology.
[25] Thomas Lengauer,et al. Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents , 2016, PloS one.
[26] T. Asselah,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.
[27] G. Dore,et al. The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis , 2015, PloS one.
[28] G. Dore,et al. Case definitions for acute hepatitis C virus infection: a systematic review. , 2012, Journal of hepatology.
[29] Tommy F. Liu,et al. Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool , 2012, Journal of Clinical Microbiology.
[30] M. Fisher. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. , 2011, AIDS.
[31] Wolters Kluwer. Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT-ID) Consensus Panel , 2020 .